Bayer HealthCare licenses Genomatix for microarray analysisGenomatix announced today that Bayer HealthCare licensed Genomatix microarray analysis platform ChipInspector. ChipInspector enables biologists and bio-informaticians to analyze chip raw data from Affymetrix GeneChip and Exon Arrays. It employs a proprietary single probe approach based on latest genomic annotation from Genomatix“ ElDorado annotation pipeline. Starting with ChipInspector the Genomatix Microarray Analysis Pipeline integrates literature and pathway mining as well as promoter analysis on sequence level in one coherent system.
"After several successful pilot studies we are now very pleased that Bayer HealthCare licensed ChipInspector. We expect that ChipInspector will enhance the Affymetrix analysis pipeline starting from GeneChip and Exon Arrays at Bayer" states Dr. Martin Seifert, VP Microarray business and collaborative research.
ChipInspector has the Affymetrix GeneChip-Compatible status.
Genomatix is a pioneer and leader in the analysis and understanding of eukaryotic gene regulation. Core competences at Genomatix are annotation driven microarray analysis, regulatory network and pathway mining, and promoter analysis on sequence level. More information is available from http://www.genomatix.de
About Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare generated sales amounting to some 9.4 billion euros and employed 33.800 people worldwide in 2005.
The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals divisions. The new Pharmaceuticals division was established on January 1, 2006, and comprises the former Biological Products and Pharmaceutical divisions. Pharmaceuticals now has three business units: Hematology/Cardiology, Oncology and Primary Care.
Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating diseases.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.